93 results about "Heart Muscle Cell" patented technology

Embodiments of the invention include additional methods and compositions for fabricating organoids. A unique approach has been developed for the rapid aggregation of defined number of cells using a micropillar-based template to limit the size of organoids, which are then more commonly referred to as spheroids. This procedure can be utilized to create in vitro cardiac tissue models (e.g., cardiac organoids) simply, rapidly, and inexpensively. In certain aspects an alginate-gelatin based hydrogel premixed with cardiomyocytes is used in combination with a patterned microfluidic chip / cell culture chamber having an array of micropillars to fabricate 3D cardiac organoids.

The present invention discloses a method for enhancing cardiomyocyte production from induced pluripotent stem cells (iPSCs) by adjusting the culture medium exchange process during the transition from WNT activation to inhibition for differentiation. Instead of completely replacing the culture medium, this innovative technique involves partially changing the medium, which allows for a controlled exposure to WNT activators concurrent with the introduction of WNT inhibitors. This key modification in the protocol markedly increases the consistency and efficiency of cardiomyocyte generation, reducing variability between batches. By fine-tuning the medium exchange process, this method streamlines the creation of cardiomyocytes for use in regenerative medicine, emphasizing the critical adjustment phase within the culture conditions.

The invention relates to the field of biological medicine. Specifically, the invention relates to a cell differentiation method based on cell dynamic image machine learning. More specifically, the present invention relates to a method and apparatus for assisting in obtaining differentiated target cells (e.g., myocardial cells) from starting cells, such as pluripotent stem cells (e.g., induced pluripotent stem cells), using machine learning of cell dynamic images.

The invention discloses a pathological autophagy detection method based on a myocardial cell sensing system. The pathological autophagy detection method comprises the following steps: constructing a pathological autophagy detection platform based on the myocardial cell sensing system, performing surface modification on a microelectrode array chip, culturing a cell autophagy sensitive element and performing in-vitro pathological autophagy detection. Through primary myocardial cell culture, rapamycin action and electrophysiological signal acquisition, time domain and frequency domain characteristics of myocardial cell extracellular local field potential signals are recorded and analyzed in real time, and the autophagy degree induced by rapamycin is judged. According to the method, the signal-to-noise ratio is improved through platinum black nanoparticle modification, it is ensured that the myocardial cell growth activity meets the detection requirement, the half inhibitory concentration of rapamycin is obtained through nonlinear regression analysis, and an effective means is provided for pathological autophagy research. The autophagy state can be obtained in real time without damaging the cell structure; any antigen or fluorescent molecular marker is not needed, so that cytotoxicity is avoided, and long-time monitoring is realized.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein identified using a high-throughput sequencing screen or rational design. In particular, the disclosure provides AAV5 virions and capsid proteins with increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

This disclosure provides compositions and methods of making cells, such as allogenic cells, engineered to evade host immune responses, particularly from T cells and natural killer cells, and populations thereof. The compositions and methods for making engineered cells include making genetic modifications that reduce or eliminate the expression of an NKG2D ligand or integrate sequences encoding HLA molecules, such as HLA-E or HLA-G. Such modifications can enhance the survival of the engineered cells within a host without impeding their ability to differentiate into functional cell types, such as cardiomyocytes.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

The invention relates to the technical field of biological medicine, in particular to application of Rab26 protein in preparation of medicine for preventing or treating cardiac hypertrophy. When the expression level of the Rab26 gene is low (less Rab26 protein is generated), the cardiac muscle cell hypertrophy degree is obviously increased; when the Rab26 gene is over-expressed (more Rab26 protein is generated), the cardiac muscle cell hypertrophy degree is obviously reduced. Therefore, the Rab26 protein is used for preparing the medicine for preventing or treating cardiac hypertrophy.

This invention provides a device and method for real-time monitoring of stem cell exosome therapy based on a cardiomyocyte sensing system, belonging to the field of micro-nano sensing and exosome therapy monitoring technology. The device includes a cell electrophysiological sensing element 1, an electrophysiological signal acquisition module 2, a signal amplification module 3, a signal display module 4, and a cell culture incubator 5. These components are sequentially connected via cables and data lines, forming a complete signal pathway. This device is used to detect the process of embryonic stem cell exosome therapy. Through multi-concentration comparison and continuous monitoring at multiple time points, it realizes the development and utilization of a new method for monitoring embryonic stem cell exosome therapy. The detection process is real-time, non-invasive, high-throughput, and highly sensitive; the detection method is efficient and simple, and has promising applications in clinical diagnosis and treatment.

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

A cell culture device and associated method for preparing an in vitro model of a neuromuscular junction (NMJ) is provided. The cell culture device has a cell culture layer (22) including a neuronal channel for receiving neuronal cells therein and a neuromuscular junction chamber in fluid communication with the neuronal channel for receiving muscle cells therein to allow co-culture of neuronal and muscle cells and form an NMJ. The neuronal channel includes a first portion having a first partial cross-section and a second portion downstream of the first portion for holding neuronal cells and having a second partial cross-section smaller than the first partial cross-section. The neuromuscular junction chamber can optionally include a support for culturing muscle cells therebetween. The in vitro model can be used, for example, to analyze biological material from a patient or to diagnose a condition.

The invention provides an application and a method of GSH in promoting mature differentiation of hiPSC-CMs, and the method is characterized in that in the process of directionally differentiating the hiPSC-CMs into the hiPSC-CMs, an effective dose of GSH is added into a differential medium, and the optimal concentration is 20-100 [mu] M. According to the invention, through simple and economical exogenous supplement of GSH, maturation of hiPSC-CMs is systematically promoted from multiple dimensions, including enhancement of intracellular anti-oxidation defense capability; energy metabolism is promoted to be converted from glycolysis to oxidative phosphorylation; up-regulating expression of cardiac muscle cell specific structural protein and calcium ion channel related genes; mitochondrial biological generation and functions are promoted; and the cell morphological structure is induced to develop to a mature phenotype. The method is simple and convenient to operate and high in biocompatibility, the hiPSC-CMs with mature functions can be stably obtained, and a high-quality cell source is provided for application of the hiPSC-CMs in the fields of heart disease modeling, drug cardiotoxicity screening and the like.

A drug development support device is provided with a processor. The processor acquires a first variation waveform, which is a variation waveform of an external potential of an iPS myocardial cell, which is a myocardial cell derived from a human iPS cell, and which is measured in a case where a candidate substance for a pharmaceutical product is added to the iPS myocardial cell while changing the addition amount of the first variation waveform, the first variation waveform being measured in accordance with the variation waveform of an external potential of the iPS myocardial cell, the iPS myocardial cell being the myocardial cell derived from the human iPS cell. Outputting, from the prediction model, a first prediction value for each addition amount for each ion channel obtained by a first prediction value indicating the degree of inhibition of the flow of ions present in a plurality of ion channels in the iPS myocardial cells by the degree of inhibition of the candidate substance; deriving, for each ion channel, an index value indicating a dose-reaction relationship of the candidate substance on the basis of the first predicted value for each addition amount; and presenting the estimated reference information corresponding to the index value and the estimated reference information referenced in order to estimate the mechanism of action based on the candidate substance to the user.

The present invention addresses the problem of providing a method for obtaining mature cardiomyocytes which can be used for screening in drug development and for cell transplantation, and said problem is solved by providing a mature cardiomyocyte production method including a step for performing partial reprogramming in immature cardiomyocytes.

This invention belongs to the field of biomedicine and regenerative medicine technology. It discloses a chimeric polypeptide, related biomaterials, and their application in inducing cardiomyocytes. The chimeric polypeptide is obtained through family homologous domain substitution and is selected from the following groups: (1) a MEF2 chimeric polypeptide with MEF2C protein as the backbone, wherein the N-terminal and C-terminal transcriptional activation domains are replaced by homologous regions of MEF2B and MEF2D, respectively; (2) a GATA chimeric polypeptide with GATA4 protein as the backbone, wherein the N-terminal transcriptional activation domain is replaced by homologous regions of GATA1 and GATA6. This invention also provides the nucleic acid encoding the polypeptide, the construct, and a method for efficiently inducing fibroblast reprogramming into cardiomyocytes under in vitro conditions. When the chimeric polypeptide of this invention is used alone or in combination, the induced cells exhibit calcium ion oscillations earlier and have higher maturity.

The present invention relates to the field of treatment and prevention of muscle wasting disorders, in particular those involving genetic factors that can be targeted by delivery of therapeutic nucleic acids to muscle cells. With the latter aspect in mind, herein disclosed are pharmaceutical compositions and advantageous components thereof that substantially facilitate effective delivery and release of therapeutic nucleic acids to the correct intracellular compartments of muscle cells, such as the cytosol and / or nucleus, where the therapeutic nucleic acid can reach and act on its genetic target. As disclosed herein, this substantial enhancement of delivery and release is achieved by providing an endosomal escape-promoting saponin in the pharmaceutical composition disclosed herein, comprising a therapeutic nucleic acid and a muscle cell targeting ligand. As demonstrated for the first time herein, this type of saponin surprisingly not only retains its endosomal escape-promoting properties in fully differentiated muscle cells, but also appears to successfully reach and enter muscle cells in vivo via an endothelial transcytosis pathway and subsequent endocytic trapping in the sarcolemma.

It relates to a composition for cryopreserving cardiomyocytes, which contains BLEB and / or PAB (or its physiologically acceptable salt) and a cryoprotectant. It also relates to a cardiomyocyte cryopreservation kit containing the composition, a method for cryopreserving mammalian cardiomyocytes with the aforementioned composition, and the use of the aforementioned composition in the preparation of a reagent for cryopreserving mammalian cardiomyocytes.

MODIFIED PEPTIDES, COMPOSITION, METHOD FOR INHIBITING MYOCYTE CONTRACTION, METHOD FOR SKIN IMPROVEMENT, AND USE OF A MODIFIED PEPTIDE. The present invention relates to modified peptides comprising an amino acid sequence of SEQ ID No. 1 to 80 and a modification of the N- and / or C-terminal ends, preferably with a modification of an acetyl and / or carboxyl group. The present invention also relates to a composition comprising said modified peptides, methods for inhibiting myocyte contraction and improving skin, and the use of said modified peptide. Figure for abstract: none

To provide an activator that can activate stem cells, myoblasts, myotube cells, muscle cells, preadipocytes, adipocytes, hepatoblasts, hepatocytes, osteoprogenitor cells, preosteoblasts, osteoblasts, bone cells, vascular cells, and blood cells; to provide a useful activator in the production of cultured meat; to provide a culture medium; to provide a culture method; and to provide a method for producing cultured meat.SOLUTION: The solution is an activator containing a plant-derived polyamine-containing extract as an active ingredient. The activator can be at least one activator selected from the group consisting of stem cells, myoblasts, myotube cells, muscle cells, preadipocytes, adipocytes, hepatoblasts, hepatocytes, osteoprogenitor cells, preosteoblasts, osteoblasts, bone cells, vascular cells, and blood cells. The activator can be used to produce cultured meat. The activator can be used as a medium additive.SELECTED DRAWING: Figure 2

Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.

The present invention relates to nanovesicles isolated from Melissa officinalis plant, the compositions comprising said nanovesicles and use of such nanovesicles and compositions. In particular, the nanovesicles for use in therapy and / or medical treatment are provided, preferably for use in prevention and / or treatment of ischaemia / reperfusion damage of cells or tissue. The nanovesicles, as provided herein, are able to enhance cell viability and regulate cell (for example, cardiomyocyte cell) contractility, thus protecting cells and tissues from damage or under stress conditions.

Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) generating receptor or a functional fragment thereof are provided. Expression vectors comprising the molecules, fusion proteins encoded by the molecules, cells, kits and pharmaceutical compositions are also provided. Methods of hyperpolarizing a cell, depolarizing a cardiac cell and treating a disease or condition are also provided.

An object of the present invention is to provide a matured cultured cell sheet comprising cardiomyocytes without using a specific drug and a method for producing the same. Another object of the present invention is to provide a method for evaluating a compound or drug using the cultured cell sheet and a method for evaluating the quality of the cultured cell sheet comprising cardiomyocytes. The cultured cell sheet of the present invention is a cultured cell sheet comprising cardiomyocytes, wherein the cardiomyocytes are arranged with alignment, and a degree of alignment determined according to the following formula (1) is 23% or more: degree of alignment (%)=(number of rod-shaped structures included within ±15° of mode) / (total number of rod-shaped structures)×100 (1), wherein in an image obtained by microscopy of the cultured cell sheet immunostained with an anti-α-actinin antibody, where a screen horizontal direction is regarded as 0°, a degree of alignment is a frequency of rod-shaped structures included within ±15° of the mode of angles which are measured in a longitudinal direction of the rod-shaped structures detected with an α-actinin antibody within a measurement range of 71.6 μm×71.6 μm.

To provide a simple and stable method for producing large quantities of cardiac organoids. [Solution] A method for producing cardiac organoids is provided, which includes culturing a mixture of pluripotent stem cell-derived cardiomyocytes and mesenchymal stem cells in a porous vessel.

Methods for inducing proliferation of cardiomyocytes in vitro and in vivo are disclosed.

The processor: acquires a first prediction value, for each ion channel and for each addition amount by which a candidate substance for a medicine is added, by causing a prediction model to output first prediction values for the degree of inhibition indicating the degree by which the flow of ions in a plurality of ion channels present in iPS cardiomyocytes is inhibited by a candidate substance, on the basis of a first variation waveform that is a variation waveform of the extracellular potential of iPS cardiomyocytes (which are cardiomyocytes derived from human iPS cells) and that is measured when the candidate substance is added to the iPS cardiomyocytes while varying the addition amount; derives, for each ion channel, an index value indicating the dose reaction relationship for the candidate substance, on the basis of the first prediction values for different addition amounts; and presents, to the user, estimation reference information that corresponds to the index value and is referred to in order to estimate the mechanism of action by the candidate substance.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

The present invention discloses a cardiomyocyte bionic taste-olfactory composite sensing system and a detection method for evaluating drugs for treating tachycardia. Cardiomyocytes that endogenously express taste receptors and olfactory receptors are used as taste-olfactory dual-sensing sensitive elements, and taste and olfactory receptors are used as drug targets. Microelectrode array potential sensors are used as secondary transducers. The system can detect the extracellular field potential signals of cardiomyocytes before and after the taste and olfactory substances act on an in vitro tachycardia model in a highly sensitive, real-time and rapid manner, and utilize time-domain and frequency-domain electrophysiological signal analysis methods to achieve the detection and quantitative evaluation of potential traditional Chinese medicines and odorants for treating tachycardia.

The invention provides application of an MAPK6 inhibitor in preparation of a medicine for treating doxorubicin cardiotoxicity, and belongs to the technical field of biological medicine. It is proved for the first time that MAPK6 and myocardial cell apoptosis caused by doxorubicin toxicity have important correlation, expression of myocardial cell apoptosis genes can be remarkably affected, then the apoptosis process is regulated and controlled, and the application prospect in the aspect of developing drugs for treating doxorubicin cardiotoxicity is achieved.